Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/article/10.1007/s11912-018-0669-y/fulltext.html
Reference42 articles.
1. •• Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. https://doi.org/10.1056/NEJMoa1609324 . This paper reported the long-term follow-up of IRIS study, the first that tested imatinib frontline.
2. Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5(9):2398–411. https://doi.org/10.1002/cam4.801 .
3. • Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chrnic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54. https://doi.org/10.1038/leu.2016.5 . This paper reported the long-term follow-up of ENESTnd trial that tested nilotinib 300 mg BID as frontline treatment.
4. • Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. https://doi.org/10.1200/JCO.2015.64.8899 . This paper reported the long-term follow-up of DASISION trial that tested dasatinib 100 mg QD as frontline treatment.
5. •• Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–5. https://doi.org/10.1038/leu.2012.104 . This paper reported the standardization provided to classify deep molecular responses in CML.
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Role of Molecular or Cytogenetic Response as a Favorable Prognostic Factor Before Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia;Transplantation and Cellular Therapy;2024-06
2. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements;Blood Cancer Journal;2024-03-26
3. How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?;British Journal of Haematology;2023-12-26
4. Exploration of treatment‐free remission in CML, based on molecular monitoring;Cancer Medicine;2023-12-22
5. Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression;Current Molecular Pharmacology;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3